Search
Close this search box.
Contact Us

Way Towards New Life

Leukemia Medications

Alleviare promptly facilitates Indian patients and physicians under Named Patient Programs (NPP) to access imported authorized medicines that are not locally available to them.
Facebook Twitter Youtube

Get access to an Leukemia - Anticancer medicine (unapproved drug in India) for personal use.

Here is a list of some of the  Leukemia Medications for which we currently have a NPP in place. If you are a patient or  healthcare professional, please click below on each to access details and information.

ZYDELIG (idelalisib) tablets

ZYDELIG is a brand-name prescription drug that’s FDA-approved to treat chronic lymphocytic leukemia (CLL),
Click here

TIBSOVO (ivosidenib tablets)

TIBSOVO is a prescription medicine used to treat: • acute myeloid leukemia (AML) with an isocitrate dehydrogenase-1 (IDH1) mutation • adults with bile duct cancer (cholangiocarcinoma)
Click here

SYNRIBO (omacetaxine mepesuccinate) for Injection

SYNRIBO for Injection is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance
Click here

MabCampath 10 mg/ml concentrate for solution for infusion

MabCampath is indicated for the treatment of patients with B-cell chronic lymphocytic leukaemia (BCLL) for whom fludarabine combination chemotherapy is not appropriate.
Click here

IDHIFA (enasidenib) tablets

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML)
Click here

ICLUSIG (ponatinib) tablets

Iclusig is FDA-approved to treat acute lymphoblastic leukemia (ALL). The drug is used to treat ALL in adults whose cancer cells have a certain gene mutation called the Philadelphia chromosome (Ph+ ALL).
Click here

Eldisine (Vindesine Sulphate) for injection

Eldisine is a cytotoxic medicine. Cytotoxic medicines kill cells which are dividing, including cancer cells. It is used to treat patients who have a cancer such as leukaemia, malignant melanoma
Click here

ERWINAZE (asparaginase Erwinia chrysanthemi) for injection

Erwinaze (asparaginase Erwinia chrysanthemi) is used to treat acute lymphoblastic leukemia (ALL) in patients who have developed hypersensitivity to E. coli-derived asparaginase.
Click here

BLINCYTO (blinatumomab) for injection

BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Click here

Atriance 5 mg/ml solution for infusion

Atriance is a brand-name prescription drug that’s FDA-approved to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).
Click here

For Indian Patient Enquiry under NPP.

Email At
kamal.kaushal@alleviareindia.com
laxmi.singh@alleviareindia.com
Call At
+91 98182 74099 ( Kamal Kaushal)
+91 9289711088 (Ms. Laxmi Singh)
WhatsApp At
+91 98182 74099 ( Kamal Kaushal)
+91 9289711088 (Ms. Laxmi Singh)

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

Access Under Named Patient Programs

Specialty Drugs

Here is a list of some of the products for which we currently have a NPP in place. If you are a patient or  healthcare professional, please click below on each to access details and information.

Lanadelumab For Injection

Approved the use of lanadelumab in August 2018, for people that are 12 years and older and have either type I or type II hereditary angioedema.
Click here

Valbenazine Capsules

It is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.
Click here

Letermovir Injection

indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Click here

Olaratumab Injection

used to treat adults with advanced soft tissue sarcoma, a type of cancer that affects the soft, supportive tissues of the body such as muscles, blood vessels and fat tissue.
Click here

Query Form

We would love to speak with you.
Feel free to reach out using the below details.

Access Unauthorized Medicines In India Under NPP.

What is Named-patient access programme (NPP)?

Named-patient basis access can also refer to a medicine for a specific patient or patients that is not (yet) authorised and available to them in their own country. Such medicine should or must (depending on legislation) be authorised in at least one country, from which it can be imported into the patient’s country under a Named-patient access programme (NPP).

These may be medicines that are:

  • Authorised but not yet available to be prescribed in the patient’s country.
  • Authorised and available in one country but not authorised and available in the patient’s country.
  • Discontinued in the patient’s country but not in another country.
  • In shortage in the patient’s country but not in another country.

Antibiotic

Arthritis

Diabetes

Genetics

Disorders

Hepatitis C

Hematologic Cancers

HIV/AIDS

Immunological Disorders

Liver Disease

Multiple Sclerosis

Nerver Disease

Oncology

Parkinson's Disease

Rare Disease

Soft Tissue Sarcoma

Transplant

Specialty Drugs

Get access to an imported medicines (unapproved drug in India) for Leukemia.

For personal use, get access to an imported medicines (unapproved drug in India) for Blood Disorders – Leukemia. On request, Anti-cancer medicines can be imported to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Karnataka, Bangalore, Bhopal, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Dispur, Guwahati, Dehradun, Lucknow, Surat, Nagpur, New Delhi, Pondichery, Pune, Itanagar, Bathinda, Thirunananthapuram, Visakhapatnam, Chandigarh, Faridabad, Gurgaon, Agartala, Shillong, Goa, Wardha, Shimla, Dharamshala, Aizawl, Noida, Ghaziabad, Punjab.

Disclaimer

All Trademarks and Brands that appear on the website belong to their respective owners. Alleviare provides only information & in any way, does not lay any claim on these brand names &/or trademarks.

Opening Hours:
Monday – Saturday 10am – 6pm
Email – contact@alleviareindia.com

Contact Address:
P: 011: 35017784 / 35017785
M/W: +91 9289711087 / 9289711088

Address:
Mezzanine Floor, S-9, Green Park Extension, South Delhi, Delhi, 110016

Instagram Facebook-f Linkedin

DISCLAIMER: The services of Alleviare Life Sciences do not replace a physician-patient relationship and are not intended as medical advice. Alleviare Life Sciences provides patients and physicians with new medicine options by providing safe and secure access to approved medicines from other countries. We only provide this service after the patient and physician have made a professional decision on the treatment.

© 2023 Alleviare Life Sciences Pvt. Ltd.

Terms and Conditions | Privacy Policy | Legal Disclaimer